sFRα shed into the circulation of ovarian cancer patients was most markedly observed at the start of neo-adjuvant and palliative treatment and was predictive of tumour cell surface but not of cytoplasmic FRα expression. The gene discussed is FOLR1; the disease is ovarian carcinoma.